• Publications
  • Influence
Atopic dermatitis.
  • T. Bieber
  • Medicine
    The New England journal of medicine
  • 2008
This paper presents a meta-anatomy of the immune response to corticosteroids and its applications in Dermatology and Allergy and investigates the role of immune “clinique” and “spatially masked” deposits.
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
Patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity, and side-effect profiles were not dose-limiting.
Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I
This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus‐based guideline, taking available
Allergic and nonallergic forms of atopic diseases.
  • N. Novak, T. Bieber
  • Medicine
    The Journal of allergy and clinical immunology
  • 1 August 2003
It is possible for the first time to delineate a new disease classification of allergic and nonallergic subtypes of atopic diseases, thereby bringing hope to the clinician for a more specific treatment approach for each subgroup of these patients.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo in two phase 3 trials of identical design.
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I
The existing evidence for treatment of atopic eczema (atopic dermatitis, AE) is evaluated using the national standard Appraisal of Guidelines Research and Evaluation. The consensus process consisted
Atopic dermatitis
Genome-Wide Scan on Total Serum IgE Levels Identifies FCER1A as Novel Susceptibility Locus
In this first genome-wide association study on total IgE FCER1A was identified and replicated as new susceptibility locus at which common genetic variation influences serum IgE levels and STAT6 was confirmed as susceptibility locu modulating IgE Levels.